Company intelligence / Profile preview

ProVerum Medical

Dublin, Ireland

Ownership: Private
Employees: ~24
Development stage: Preclinical

Overview

ProVerum’s lead product, the ProVee stent system, demonstrated successful deployment in all patients in its first-in-human study with immediate and durable improvement in BPH symptoms. No device-related serious adverse events were reported through two years of follow-up. The company received FDA IDE approval in December 2021 to commence its pivotal US trial; as of March 2024, enrollment for the pivotal study was completed[8][4].

Therapeutic areas: Men's Health
Modalities: DeviceImplant
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on ProVerum Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProVerum Medical.

Explore the full profile